Change in designation of Mr. Venkata Rao Sadhanala, whole Time director as Managing Director of the company for a period of 5 years w.e.f. March 11, 2026, subject to approval of shareholders.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The board of Venmax Drugs and Pharmaceuticals, at its meeting on March 11, 2026, approved the elevation of Mr. Venkata Rao Sadhanala from Whole Time Director to Managing Director for a 5-year term ending March 10, 2031. The appointment is subject to shareholder approval at the next general meeting. Mr. Sadhanala is a qualified Chartered Accountant and Company Secretary with over 30 years of experience in banking, finance, FMCG, and pharma sectors, and has previously held senior positions at Vanta Bioscience Ltd and Synergy Castings Ltd. His remuneration has been set at Rs. 30 lakhs per annum inclusive of perquisites. The change is a redesignation rather than a fresh external hire, as he was already serving on the board.
This is an internal leadership elevation with a defined 5-year term, which provides continuity at the top. For shareholders, the key action item is the pending approval at the next general meeting; no immediate material impact on stock price is expected.